普拉克索联合多巴丝肼对帕金森患者运动功能及血清Hcy、IGF-1水平的影响

Effect of praxso combined with dopashydrazine on motor function and serum Hcy,IGF-1 levels in Parkinson patients

目的探讨普拉克索联合多巴丝肼对帕金森患者运动功能及血清同型半胱氨酸(Hcy)、胰岛素样生长因子(IGF-1)水平的影响。方法选取2017年3月至2019年3月在本院就诊的104例帕金森患者,随机分为观察组与对照组,各52例。对照组接受多巴丝肼治疗,观察组在对照组基础上联合普拉克索治疗。治疗6个月后,比较两组疗效、运动功能及血清相关指标。结果观察组治疗总有效率(92.31%)高于对照组(76.92%)(P<0.05);治疗后,两组MDRSPD评分均下降,且观察组低于对照组(P<0.05);治疗后,两组Hcy均降低,IGF-1均升高,且观察组优于对照组(P<0.05)。结论普拉克索联合多巴丝肼治疗帕金森患者,可降低机体Hcy水平,提高IGF-1水平,减轻神经元损伤,改善运动功能,治疗效果显著。

Objective To investigate the effect of praxso combined with dopazazine on motor function and serum homocysteine(Hcy)and insulinlike growth factor(IGF-1)levels in Parkinson patients.Methods 104 Parkinson patients treated in the hospital from March 2017 to March 2019 were randomly divided into observation group and control group,with 52 cases in each group.The control group was treated with dopbaszid and the observation group combined with Plaxso on the basis of the control group.After 6 months of treatment,the efficacy,motor function and serum-related indicators were compared between two groups.Results The total efficiency(92.31%)in the observation group was higher than the control group(76.92%)(P<0.05).After treatment,MDRSPD score in both groups decreased,and the observation group was lower than the control group(P<0.05);after treatment,Hcy decreased and IGF-1 increased in both groups,and the observation group was better than the control group(P<0.05).Conclusion Pramipexole combined with dopashydrazine treat the patients with Parkinson's disease can reduce the level of Hcy and increase the level of IGF-1,so as to reduce neuronal injury and improve motor function,the therapeutic effect is remarkable.